PRAX Stock Risk & Deep Value Analysis
Praxis Precision Medicines Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PRAX Stock
We analyzed Praxis Precision Medicines Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PRAX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PRAX Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is a negative regulatory decision for either relutrigine or ulixacaltamide at their respective PDUFA dates. A rejection or significant delay for these lead commercial assets would drastically impact Praxis's valuation and ability to fund future operations.
Risk Matrix
Overall
Aggressive
Financial
Low
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
High reliance on binary regulatory approval events for lead pipeline assets, creating significant stock volatility.
- ⚠
Increasing cash burn rate ($86M operating cash used in Q1 2026), requiring successful commercialization or future financing post-2028.
- ⚠
Significant increase in G&A expenses (up 100% YoY), reflecting the high cost of transitioning to a commercial-stage company.
Upcoming Risk Events
- 📅
Negative PDUFA outcomes (e.g., Complete Response Letter) or significant delays for relutrigine or ulixacaltamide.
- 📅
Failure or inconclusive results from POWER1 or EMERALD clinical trials.
- 📅
Slower-than-expected commercial uptake of approved drugs due to competition or market access challenges.
When to Reconsider
- 🚪
Regulatory rejection (Complete Response Letter) for either ulixacaltamide or relutrigine.
- 🚪
Failure of either POWER1 or EMERALD clinical trials to meet primary endpoints or showing unexpected safety issues.
- 🚪
Cash balance falling below $500M without a clear and de-risked financing strategy or strong revenue ramp.
Unlock PRAX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Praxis Precision Medicines Inc (PRAX) Do?
Market Cap
$9.63B
Sector
Healthcare
Industry
Biotechnology
Employees
116
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050. In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
Visit Praxis Precision Medicines Inc WebsiteInvestment Thesis
Praxis Precision Medicines offers compelling 10x growth potential driven by its de-risked late-stage CNS pipeline, with two NDAs accepted by the FDA (relutrigine with priority review, ulixacaltamide). The company's strengthened cash position provides a substantial runway, enabling it to execute on commercialization and further pipeline development in large, underserved markets, positioning it for significant value creation post-approvals.
Is PRAX Stock Undervalued?
Unlock the full AI analysis for PRAX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PRAX Price Targets & Strategy
12-Month Target
$550.00
Bull Case
$750.00
Bear Case
$150.00
Valuation Basis
Implied valuation of ~$15.3B based on successful regulatory approvals for relutrigine (Sept 2026) and ulixacaltamide (Jan 2027) and anticipated rapid ramp-up towards multi-billion dollar peak sales for lead assets.
Entry Strategy
Consider dollar-cost averaging on any dips towards $300-$320 (near recent support levels) to build a position ahead of critical PDUFA catalysts.
Exit Strategy
Take partial profits at $550 and re-evaluate upon PDUFA outcomes. Place a stop loss below $250 if significant regulatory or clinical setbacks occur.
Portfolio Allocation
7-10% for aggressive risk tolerance, 3-5% for moderate, given the high-risk, high-reward biotech profile.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is PRAX Financially Healthy?
Valuation
P/E Ratio
69.60
Forward P/E
7.70
EV/EBITDA
-2.90
PEG Ratio
0.19
Price/Book
20.10
Price/Sales
78.40
Profitability
Gross Margin
98.00%
Operating Margin
-2340.29%
Net Margin
-2137.48%
Return on Equity
-58.74%
Revenue Growth
62.00%
EPS
$-13.45
Balance Sheet
Current Ratio
10.22
Quick Ratio
10.03
Debt/Equity
0.05
Total Debt
$21.00M
Cash & Equivalents
$320.00M
Cash Flow
Operating Cash Flow
-$164.00M
Free Cash Flow
-$176.00M
EBITDA
-$91.00M
Other
Beta (Volatility)
2.79
Does PRAX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is strengthening as lead candidates approach and achieve regulatory approval, translating scientific innovation into market-protected assets. Patented novel mechanisms provide a period of exclusivity, and the specialized, severe nature of the target conditions can create high switching costs once patients are stabilized on therapy, especially for rare genetic epilepsies.
Moat Erosion Risks
- •Failure to achieve regulatory approval or successful commercialization for lead assets, which would significantly undermine the value of intellectual property.
- •Emergence of superior or me-too therapies from larger competitors that offer better efficacy, safety profiles, or ease of administration.
- •Patent expiry or successful legal challenges leading to generic competition in the long term, reducing exclusivity.
PRAX Competitive Moat Analysis
Sign up to see competitive advantages
PRAX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Specific social media sentiment data was not provided, but biotech stocks are typically subject to volatile retail investor sentiment around key clinical and regulatory milestones.
Institutional Sentiment
Positive. Significant stakes held by institutional investors like Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd (8.9% combined), and Baker Bros. Advisors (6.3%), indicating strong conviction from experienced biotech specialists.
Insider Activity (Form 4)
No specific Form 4 insider purchase/sale filings were included in the provided search results for the last 90 days. Institutional ownership updates were filed on May 13, 2026.
Options Flow
Normal options activity. No specific unusual options activity was reported in the provided research to indicate strong directional institutional positioning.
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026 results)
Surprise Probability
Medium. Q1 EPS beat expectations, but revenue is nascent. Surprise potential hinges on early commercialization insights and updates on pipeline milestones rather than traditional financial performance.
Historical Earnings Pattern
As an early-commercial biotech, stock reactions are highly sensitive to pipeline progress, regulatory news, and clinical trial results rather than quarterly financials alone. Positive clinical/regulatory updates typically lead to significant rallies; negative news results in sharp declines.
Key Metrics to Watch
Competitive Position
Top Competitor
Biogen (BIIB) / Harmony Biosciences (HRMY) - *These represent established CNS players; specific direct competitors targeting Praxis' novel mechanisms were not provided in the research.*
Market Share Trend
Gaining. Praxis is positioned to create or capture significant market share in highly specialized, underserved CNS indications with novel therapeutic mechanisms, rather than competing directly for existing market share in saturated markets.
Valuation vs Peers
Praxis currently trades at a significant premium on traditional valuation metrics (e.g., P/E, P/S) compared to established, profitable CNS companies. Its valuation is primarily driven by the discounted net present value of its late-stage pipeline assets and future peak sales potential, rather than current earnings.
Competitive Advantages
- •Proprietary pipeline with novel mechanisms of action addressing specific CNS disorder pathways.
- •Strong intellectual property protection for lead drug candidates (ulixacaltamide, relutrigine).
- •Targeting highly specific, underserved patient populations (e.g., SCN2A/SCN8A DEEs) with high unmet medical need.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive PRAX Stock Higher?
Near-Term (0-6 months)
- •Relutrigine (SCN2A/SCN8A DEEs) PDUFA target date: Sept 27, 2026 (Priority Review)
- •POWER1 topline results expected this quarter (Q2 2026)
- •EMERALD readout expected in Q4 2026
Medium-Term (6-18 months)
- •Ulixacaltamide (Essential Tremor) PDUFA target date: Jan 29, 2027
- •Initial commercial launch and ramp-up for approved assets (H2 2026 - H1 2027)
- •Advancement of vormatrigine in focal epilepsy pipeline and further clinical data
Long-Term (18+ months)
- •Establishment of market leadership in precision CNS neuroscience through a diversified pipeline.
- •Expansion of approved therapeutics into broader indications or new geographical markets.
- •Development and commercialization of next-generation neurological disorder treatments.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for PRAX?
- ✓
Successful FDA approval and initial market uptake data for relutrigine, providing critical commercial validation.
- ✓
Positive topline results for POWER1 and EMERALD trials, confirming pipeline depth and potential.
- ✓
Management's ability to maintain cash runway and control burn post-commercialization, demonstrating financial prudence.
Bull Case Analysis
Sign up free to see the bull case
Competing with PRAX
See how Praxis Precision Medicines Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Praxis Precision Medicines Inc PRAX | $9.6B | 8.6 | 69.6 | $30.0M | -2137.5% | 62.0% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Praxis Precision Medicines Inc Makes Money
Praxis Precision Medicines is a clinical-stage and early-commercial biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics for central nervous system (CNS) disorders. The company's strategy involves identifying and advancing proprietary drug candidates that precisely modulate specific ion channels and neuronal pathways to address the underlying causes of neurological conditions such as essential tremor and various forms of epilepsy. Its business model transitions from solely R&D-driven to generating revenue primarily through product sales of approved therapies (which are just beginning), supplemented by potential milestone payments from strategic partnerships or licensing agreements.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Praxis Precision Medicines Inc (PRAX)?
As of May 16, 2026, Praxis Precision Medicines Inc has a DVR Score of 8.6 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Praxis Precision Medicines Inc?
Praxis Precision Medicines Inc's market capitalization is approximately $9.6B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Praxis Precision Medicines Inc use?
PRAX is the ticker symbol for Praxis Precision Medicines Inc. The company trades on the NMS.
What is the risk level for PRAX stock?
Our analysis rates Praxis Precision Medicines Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PRAX?
Praxis Precision Medicines Inc currently has a price-to-earnings (P/E) ratio of 69.6. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is Praxis Precision Medicines Inc's revenue growing?
Praxis Precision Medicines Inc has reported revenue growth of 62.0%. The company is showing strong top-line momentum.
Is PRAX stock profitable?
Praxis Precision Medicines Inc has a profit margin of -2137.5%. The company is currently unprofitable.
How often is the PRAX DVR analysis updated?
Our AI-powered analysis of Praxis Precision Medicines Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PRAX (Praxis Precision Medicines Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.